Please find enclosed herewith the financial results for the Quarter and Nine Months ended 31st December 2025, pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Genomic Valley Biotech reported weak standalone unaudited results for Q3 and nine months ended December 31, 2025. Revenue from operations for Q3 fell sharply to about Rs. 5 lakh from Rs. 22 lakh in the year-ago quarter, and nine-month revenue declined to roughly Rs. 23 lakh versus Rs. 58 lakh last year. Profit after tax for nine months shrank to about Rs. 3.85 lakh from Rs. 43 lakh earlier, though the company stayed marginally profitable. Additionally, director Mr. Ashok Kumar (DIN: 07647876) ceased with immediate effect citing Section 167 of the Companies Act and non-completion of KYC. The statutory auditor issued an unmodified limited review report.
Sharp revenue and profit contraction is a red flag for this small-cap biotech and may weigh negatively on investor confidence and the stock price. The director exit over compliance issues adds to governance concerns.